Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) EBITDA Margin: 2020-2025

Historic EBITDA Margin for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Sep 2025 value amounting to 1.96%.

  • Mirum Pharmaceuticals' EBITDA Margin rose 1599.00% to 1.96% in Q3 2025 from the same period last year, while for Sep 2025 it was -8.86%, marking a year-over-year increase of 2240.00%. This contributed to the annual value of -26.00% for FY2024, which is 3256.00% up from last year.
  • Per Mirum Pharmaceuticals' latest filing, its EBITDA Margin stood at 1.96% for Q3 2025, which was up 150.13% from -3.90% recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' EBITDA Margin ranged from a high of 1,408.25% in Q1 2021 and a low of -1,452.36% during Q4 2021.
  • In the last 3 years, Mirum Pharmaceuticals' EBITDA Margin had a median value of -31.12% in 2024 and averaged -33.95%.
  • Per our database at Business Quant, Mirum Pharmaceuticals' EBITDA Margin slumped by 1,248,251bps in 2021 and then surged by 132,994bps in 2022.
  • Mirum Pharmaceuticals' EBITDA Margin (Quarterly) stood at -1,452.36% in 2021, then spiked by 132,994bps to -122.41% in 2022, then skyrocketed by 7,557bps to -46.85% in 2023, then surged by 2,248bps to -24.36% in 2024, then surged by 1,599bps to 1.96% in 2025.
  • Its EBITDA Margin stands at 1.96% for Q3 2025, versus -3.90% for Q2 2025 and -13.61% for Q1 2025.